Teleflex Receives FDA Clearance for the Wattson® Temporary Pacing Guidewire
07 Junho 2023 - 7:30AM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced it will feature the Wattson®
Temporary Pacing Guidewire – the first commercially available
bipolar temporary pacing guidewire designed specifically for use
during TAVR and BAV – at TVT: The Structural Heart Summit, June
7-10 at the Phoenix Convention Center-West.
Featuring a simple design to create procedural efficiencies, the
Wattson® Temporary Pacing Guidewire offers dual functionality,
supporting both valve delivery and ventricular bipolar pacing
during TAVR or BAV procedures. The device offers a procedural
alternative designed to help avoid a range of complications1,
steps1, and costs2 associated with traditional right ventricular
pacing. From its flexible distal pigtail shape to its multiple
electrode, bipolar design, the Wattson® Temporary Pacing Guidewire
is engineered to help reduce the risk of ventricular perforation
while providing confidence in capture during rapid pacing.
“This technology enables us to provide physicians with a new
tool specifically engineered to address unmet clinical needs
frequently encountered during TAVR or BAV procedures,” said Jake
Newman, President of The Americas at Teleflex. “The Wattson®
Temporary Pacing Guidewire reflects our focus on purposeful
innovation and commitment to providing more options to further
simplify minimalist TAVR and other structural procedures.”
The Wattson® Temporary Pacing Guidewire will enter a limited
market release phase, with full market release anticipated later
this year.
About Teleflex
IncorporatedTeleflex is a global provider of
medical technologies designed to improve the health and quality of
people’s lives. We apply purpose driven innovation – a relentless
pursuit of identifying unmet clinical needs – to benefit patients
and healthcare providers. Our portfolio is diverse, with solutions
in the fields of vascular access, interventional cardiology and
radiology, anesthesia, emergency medicine, surgical, urology and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®,
QuikClot®, Rusch®, UroLift® and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
References:
- Clinical Investigation: TEMPORARY
PACING GUIDEWIRE STUDY. Testing completed by Teleflex. Data on file
with Teleflex. Bench test results may not necessarily be indicative
of clinical performance.
- Faurie B, Souteyrand G, Staat P,
Godin M, Caussin C, Van Belle E, Mangin L, Meyer P, Dumonteil N,
Abdellaoui M, Monségu J, Durand-Zaleski I, Lefèvre T; EASY TAVI
Investigators. Left Ventricular Rapid Pacing
Via the Valve Delivery Guidewire in Transcatheter Aortic
Valve Replacement. JACC Cardiovasc Interv. 2019 Dec
23;12(24):2449-2459.
CAUTION: Federal (USA) law restricts these devices for sale or
use by or on the order of a physician.
Teleflex, the Teleflex logo, Arrow, Deknatel, GuideLiner, LMA,
Pilling, QuikClot, Rusch, UroLift, Wattson, and Weck are trademarks
or registered trademarks of Teleflex Incorporated or its affiliates
in the U.S. and/or other countries. Refer to the Instructions
for Use for a complete listing of the indications,
contraindications, warnings, and precautions. Information in this
document is not a substitute for the product Instructions for
Use. Not all products may be available in all countries.
Please contact your local representative.
© 2023 Teleflex Incorporated. All rights reserved.
MC-008983.
Contacts:
For Teleflex Incorporated:Lawrence KeuschVice President,
Investor Relations and Strategy Development
investor.relations@teleflex.com610.948.2836
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024